Novavax Inc
NVAX6.773USD
+0.213+3.25%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.10BCap. mercado
2.29P/E TTM
Más Datos de Novavax Inc Compañía
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Información de la empresa
Símbolo de cotizaciónNVAX
Nombre de la empresaNovavax Inc
Fecha de salida a bolsaMay 16, 1973
Director ejecutivoMr. John C. Jacobs
Número de empleados952
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 16
Dirección700 Quince Orchard Road
CiudadGAITHERSBURG
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal20878
Teléfono12402682000
Sitio Webhttps://www.novavax.com/?locale=US
Símbolo de cotizaciónNVAX
Fecha de salida a bolsaMay 16, 1973
Director ejecutivoMr. John C. Jacobs
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
136.73K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+17.11%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+19.18%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
36.01K
+40.72%
Ms. Rachel K. King
Ms. Rachel K. King
Independent Director
Independent Director
35.61K
+41.37%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
35.11K
+42.20%
Mr. Mark J. Casey
Mr. Mark J. Casey
Executive Vice President, Chief Legal Officer, Company Secretary
Executive Vice President, Chief Legal Officer, Company Secretary
31.97K
--
Mr. James Patrick (Jim) Kelly
Mr. James Patrick (Jim) Kelly
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
--
--
Dr. Robert Walker, M.D.
Dr. Robert Walker, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
136.73K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+17.11%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+19.18%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
36.01K
+40.72%
Ms. Rachel K. King
Ms. Rachel K. King
Independent Director
Independent Director
35.61K
+41.37%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
Canada
575.67M
86.38%
Rest of the world
43.29M
6.50%
United States
39.41M
5.91%
Europe
8.09M
1.21%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 4 de jun
Actualizado: mié., 4 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.66%
BlackRock Institutional Trust Company, N.A.
7.14%
Shah Capital Management, Inc.
7.11%
State Street Global Advisors (US)
4.35%
Sanofi SA
4.25%
Other
67.50%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.66%
BlackRock Institutional Trust Company, N.A.
7.14%
Shah Capital Management, Inc.
7.11%
State Street Global Advisors (US)
4.35%
Sanofi SA
4.25%
Other
67.50%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
22.62%
Investment Advisor/Hedge Fund
18.46%
Hedge Fund
10.75%
Corporation
8.26%
Research Firm
4.80%
Pension Fund
0.81%
Individual Investor
0.52%
Bank and Trust
0.43%
Venture Capital
0.04%
Other
33.30%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
550
108.02M
66.69%
-12.99M
2025Q1
575
113.82M
70.29%
-16.33M
2024Q4
593
111.51M
69.72%
-5.93M
2024Q3
597
103.31M
64.96%
-4.25M
2024Q2
652
92.80M
65.79%
-10.97M
2024Q1
753
86.51M
64.06%
-11.91M
2023Q4
848
86.68M
74.23%
+6.21M
2023Q3
919
70.31M
60.51%
-6.00M
2023Q2
957
58.87M
62.55%
-19.22M
2023Q1
1015
61.08M
70.93%
-3.17M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
15.64M
9.66%
-57.51K
-0.37%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
11.56M
7.14%
-518.90K
-4.30%
Mar 31, 2025
Shah Capital Management, Inc.
11.13M
6.87%
-17.00K
-0.15%
Mar 31, 2025
State Street Global Advisors (US)
7.04M
4.35%
-662.21K
-8.60%
Mar 31, 2025
Sanofi SA
6.88M
4.25%
--
--
Mar 31, 2025
SK Bioscience Co., Ltd.
6.50M
4.01%
--
--
May 10, 2024
Coatue Management, L.L.C.
3.84M
2.37%
+3.84M
--
Mar 31, 2025
Geode Capital Management, L.L.C.
3.76M
2.32%
+106.31K
+2.91%
Mar 31, 2025
D. E. Shaw & Co., L.P.
3.26M
2.01%
-2.53M
-43.68%
Mar 31, 2025
Park West Asset Management LLC
2.53M
1.56%
+2.53M
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ProShares Nanotechnology ETF
2.42%
iShares Genomics Immunology and Healthcare ETF
2.14%
Virtus LifeSci Biotech Products ETF
1.7%
ALPS Medical Breakthroughs ETF
0.69%
SPDR S&P Biotech ETF
0.41%
Direxion Daily S&P Biotech Bull 3X Shares
0.23%
Invesco Nasdaq Biotechnology ETF
0.11%
First Trust Small Cap Growth AlphaDEX Fund
0.11%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Biotechnology ETF
0.1%
Ver más
ProShares Nanotechnology ETF
Proporción2.42%
iShares Genomics Immunology and Healthcare ETF
Proporción2.14%
Virtus LifeSci Biotech Products ETF
Proporción1.7%
ALPS Medical Breakthroughs ETF
Proporción0.69%
SPDR S&P Biotech ETF
Proporción0.41%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.23%
Invesco Nasdaq Biotechnology ETF
Proporción0.11%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.11%
ProShares Ultra Nasdaq Biotechnology
Proporción0.11%
iShares Biotechnology ETF
Proporción0.1%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
